After An Approx. 42% Jump in Today’s AI Profile—Veru (NASDAQ: VERU) Tops Tomorrow’s Watchlist—Here’s Why

*Sponsored After Today’s AI Profile Moved Approximately 42% Before the Bell—It’s Time To See What Just Hit Our Radar For Tomorrow—Tuesday, 4/4/2025. Veru Inc. (NASDAQ: VERU) Is Our Next Potential Breakout Idea… And Here’s Why… Targeting A Rapidly Growing Segment With Forecasts Pointing To 900%+ Growth And Over $470B In Scale. Preparing For A Pivotal FDA-Regulated Phase 3 Trial To Advance A Muscle-Selective Approach. Backed By Dr. Phillip Frost, Who’s Worth Over $2B And Holds Over 5M Shares While Bringing A Long Track Record In Healthcare. Covered By Four Major Firms With One Target Suggesting An Upside Potential Of Over 716% From Today’s $.49 Range. Take A Look At Veru Inc. (NASDAQ: VERU) Before Tomorrow Morning… March 31, 2025 Dear Reader, After today’s “AI” profile showcased an approximate 42% move, from $2.02 to $2.88, before the bell even rang, we’re now turning our focus to what’s coming up next. Every once in a while, a pattern emerges before most people recognize what it means. You see early movement in a fast-changing sector. Then a familiar name steps in quietly. Soon after, analysts begin aligning with bold outlooks. And just like that, something that once looked obscure is suddenly everywhere. That setup is unfolding right now. A global healthcare shift is accelerating—one that’s projected to expand by more than 900%, reaching over $470B in size.  And while attention is locked on the giants of the sector, one relatively unknown company is positioning itself with the right science, the right timing, and now… the right people backing it. Let’s take a closer look at Veru Inc. (NASDAQ: VERU). A Heavy Hitter Steps In… When someone like Dr. Phillip Frost takes a position, it’s not a throwaway move. This is someone with a long, public track record of spotting where things are headed—and backing companies early with both conviction and capital. Dr. Frost currently holds a net worth exceeding $2B, and his past includes building and exiting some of the most well-known pharmaceutical names in the business. That includes: Key Pharmaceuticals, which he helped scale before it was sold for $836M Ivax, which he led before its $7.6B acquisition by Teva Pharmaceuticals Frost owns over 5M shares of Veru Inc. (NASDAQ: VERU). For someone who could allocate capital anywhere, this kind of commitment speaks volumes. Institutional Analysts Are Starting to Weigh In… While Veru Inc. (NASDAQ: VERU) has remained relatively quiet in mainstream headlines, several top-tier research firms have initiated or updated their outlooks—and they’re not subtle about what they see. Here’s what the current targets look like: B. Riley Financial: $2 target (308% potential upside.) H.C. Wainwright & Co.: $2.50 target (410% potential upside.) Raymond James: $3 target (512% potential upside.) Oppenheimer: $4 target (716% potential upside.) Each target suggests significant upside potential from today’s $.49 range—which could indicate Veru Inc. (NASDAQ: VERU)’s recent progress may be deeply underappreciated by the broader market. This kind of alignment from respected firms, combined with a well-timed move from someone like Dr. Frost is usually the kind of thing that deserves a closer look. Here’s What Makes Veru Inc. (NASDAQ: VERU) Different… At the heart of While Veru Inc. (NASDAQ: VERU)’s development pipeline is Enobosarm—a compound with a very specific focus: Reducing fat while preserving muscle mass. That might sound simple, but it addresses one of the most pressing—and often ignored—problems in the fast-growing wei-ght management category: unintended muscle loss. Many existing therapies are successful at reducing wei-ght on the scale—but they also reduce lean body mass, including muscle and bone density.  That creates long-term challenges for patients, especially those managing age-related conditions or chronic illness. While Veru Inc. (NASDAQ: VERU)’s science is aiming to solve that issue. In its Phase 2b QUALITY trial, Enobosarm was evaluated alongside a widely used metabolic therapy. The results? Reduction in fat mass Preservation of lean muscle Improved body composition overall That’s not just clinically meaningful—it could change the way this entire segment of care is approached. And now, Veru Inc. (NASDAQ: VERU) is preparing for a pivotal Phase 3 trial, with plans for further development under FDA regulation already in motion. But beyond analyst targets and headlines, the real strength of this story lies in the science—and the path forward. When you combine early clinical data with a clear development roadmap, strong internal resources, and growing institutional interest, a clearer picture starts to form. 7 Reasons Why Veru Inc. (NASDAQ: VERU) Is Topping Our Watchlist Tomorrow Morning… 1. Targeting One of the Fastest-Growing Segments in Healthcare: The metabolic health category is expanding rapidly—with forecasts pointing to 900%+ growth and over $470B in total size. Veru Inc. (NASDAQ: VERU) is pursuing a highly differentiated solution inside that transformation. 2. Solving a Real Clinical Problem: While others chase general wei-ght reduction, Veru Inc. (NASDAQ: VERU) is focusing on body composition—an issue that directly affects patient quality of life and long-term safety. 3. Clinical Data That Supports the Strategy: Its Phase 2b results showed that Enobosarm, when combined with existing therapies, may allow for fat loss without muscle degradation—offering a potentially better approach for a wide range of patients. 4. A Clear Path Forward: A Phase 3 trial is in planning. With FDA oversight, this next step could be pivotal in establishing Veru Inc. (NASDAQ: VERU)’s compound as a legitimate option in a space that’s currently lacking muscle-selective treatments. 5. Heavy-Hitter Backed: Dr. Phillip Frost isn’t just lending his name—he’s taken a stake—securing 5M shares. His track record of backing successful exits adds wei-ght to Veru Inc. (NASDAQ: VERU)’s future. 6. Analysts Aren’t Just Watching—They’re Setting Big Targets: The coverage from four major firms shows growing confidence from those who’ve done deep due diligence. Their targets suggest a disconnect between where Veru Inc. (NASDAQ: VERU) is today—and where it may be headed. 7. Strong Ca-sh Position to Keep Moving: With over $26M in cash and equivalents, Veru Inc. (NASDAQ: VERU) is positioned to advance its clinical pipeline without immediate capital concerns.  Consider Adding Veru Inc. (NASDAQ: VERU) To Your Radar Before  Tomorrow Morning… Veru Inc. (NASDAQ: VERU) stands out not just for where it's positioned—but for how it's approaching one of the most critical healthcare trends of the decade. While much of the field remains focused on general wei-ght loss, Veru Inc. (NASDAQ: VERU) is advancing a body composition strategy backed by real clinical data—targeting fat reduction without the loss of lean muscle.  That distinction could matter greatly as the metabolic health space continues to expand—by over 900%, according to some projections. Its next steps are already in motion: a pivotal Phase 3 trial, FDA oversight, and a growing list of analysts pointing to what may be meaningful revaluation ahead.  With a strong ca-sh position and a seasoned healthcare heavy-hitter like Dr. Phillip Frost behind it, Veru Inc. (NASDAQ: VERU) is positioned to keep moving forward with momentum. We will have all eyes on (VERU) tomorrow morning—4/1/2025. Consider taking a look at (VERU) before you call it a night. Also, keep a lookout for my morning update—it could be coming early. Have a good night. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and Goldwyn Media LLC, TD Media LLC has been hired for a period beginning on 03/17/2025 and ending on 04/01/2025 to publicly disseminate information about (VERU:US) via digital communications. Under this agreement, TD Media LLC has been paid one hundred seventy five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (VERU:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/veru/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice